Green Cross obtains exclusive distribution rights for somatostatin injection

Published: 2009-07-29 06:58:00

Updated: 2009-07-29 06:58:00

Green Cross Corporation said on July 24 it has signed an agreement with he Korean subsidiary of Merck KGaA Germany for the exclusive distribution rights in Korea for Stilamin injection (somatostatin acetate).

Somatostain injection was developed by Merck KGaA for the treatment of acute variceal...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK